Atezolizumab/ipilimumab/pembrolizumabColitis and ulcer: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1699卷 / 1期

关键词：

D O I：

10.1007/s40278-018-45309-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：40 / 40

相关论文

共 50 条

[1] Atezolizumab/ipilimumab/pembrolizumabColitis and ulcer: 3 case reports
Reactions Weekly, 2018, 1700 (1) : 48 - 48
[2] Aspirin/ipilimumab/pembrolizumabColitis: 2 case reports
Reactions Weekly, 2019, 1745 (1) : 66 - 66
[3] Ipilimumab/nivolumab/pembrolizumabColitis: 6 case reports
Reactions Weekly, 2022, 1909 (1) : 301 - 301
[4] Ipilimumab/pembrolizumabColitis and pneumonitis: 2 case reports
Reactions Weekly, 2017, 1633 (1) : 426 - 426
[5] Ipilimumab/nivolumab/pembrolizumabColitis: 2 case reports
Reactions Weekly, 2020, 1808 (1) : 161 - 161
[6] Atezolizumab/ipilimumab/nivolumabLymphocytic colitis : 3 case reports
Reactions Weekly, 2018, 1700 (1) : 47 - 47
[7] Atezolizumab/ipilimumab/nivolumabLymphocytic colitis: 3 case reports
Reactions Weekly, 2018, 1699 (1) : 39 - 39
[8] Atezolizumab/ipilimumab/nivolumabHyperglycaemia: 10 case reports
Reactions Weekly, 2021, 1853 (1) : 76 - 76
[9] Ipilimumab/pembrolizumabColitis: case report
Reactions Weekly, 2020, 1793 (1) : 257 - 257
[10] Atezolizumab/ipilimumab/pembrolizumabFacial paralysis: 2 case reports
Reactions Weekly, 2019, 1765 (1) : 62 - 62

← 1 2 3 4 5 →